Stockscreener 앱 받기
6.1401
3.72%
0.2201
전일 마감가:
$5.92
열려 있는:
$5.99
하루 거래량:
41,514
Relative Volume:
0.22
시가총액:
$306.85M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+2.68%
1개월 성능:
-20.57%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$5.98
$6.1658
1주일 범위
$5.76
$7.19
52주 변동 폭
$5.76
$8.23
Helus Pharma Inc Stock (HELP) Company Profile
Compare HELP vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HELP
Helus Pharma Inc
|
6.15 | 295.37M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.42 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
797.23 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
839.43 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.72 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
350.58 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-02 | 개시 | Jefferies | Buy |
| 2025-03-13 | 개시 | Guggenheim | Buy |
| 2021-11-19 | 다운그레이드 | Maxim Group | Buy → Hold |
Helus Pharma Inc 주식(HELP)의 최신 뉴스
Helus Pharma (HELP) Advances Neuro Portfolio with Robust Financial Position - GuruFocus
Cybin (Helus Pharma) Posts Higher Assets, Equity and Losses in Q3 FY2026 SEC Filing - TipRanks
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - Toronto Star
Helus Pharma appoints Michael Cola as CEO - The Pharma Letter
Helus Pharma Names Michael Cola As CEO For Next Phase Of Growth - bernama
HELUS PHARMA NAMES MICHAEL COLA AS CEO FOR NEXT PHASE OF GROWTH - bernama
Helus Pharma appoints Michael Cola as CEO amid clinical trial milestones By Investing.com - Investing.com South Africa
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution - wahanariau.com
Helus Pharma Appoints Michael Cola as Chief Executive Officer, Effective February 10, 2026 - marketscreener.com
Taking the Helm at Helus: A Brief Q&A With New CEO Michael Cola - Psychedelic Alpha
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market - Newswire Canada
Helus Pharma appoints Michael Cola as CEO amid clinical trial milestones - Investing.com Canada
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and ... - Caledonian Record
Will Helus Pharma's GAD Trial Data Calm Investor Anxiety? - RTTNews
Jefferies initiates Helus Pharma stock with Buy rating on upcoming catalysts - Investing.com Canada
Jefferies initiates Helus Pharma stock with Buy rating on upcoming catalysts By Investing.com - Investing.com South Africa
Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts Hold on GH Research’s 5-MeO-DMT IND; Compass Details Pivotal PTSD Trial Design; Cybin Becomes Helus - Psychedelic Alpha
Breakthrough or Bubble? The High-Stakes 2026 Readouts for Psychedelic Giants - geneonline.com
Psychedelic Funding, Public Markets, and M&A in 2025 - Psychedelic Alpha
The Psychedelic News Feed: January 1218, 2026 - Psychedelic Alpha
Definium points the way forward as MindMed drops old identity - Fierce Pharma
The Psychedelic News Feed: January 0511, 2026 - Psychedelic Alpha
Why Cybin (HELP) Is Down 9.1% After Rebranding To Helus And Relisting On Nasdaq - Yahoo Finance
Assessing Cybin’s Valuation As Helus Pharma Uplists To Nasdaq And Joins The Nasdaq Composite Index - Sahm
Helus Pharma Rings the Opening Bell - Nasdaq
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq - bernama
Helus Pharma Rebrands, Debuts On Nasdaq - bernama
Cybin (CYBN) Is Down 9.8% After Launching US$100M At-The-Market Equity ProgramWhat's Changed - simplywall.st
HELUS PHARMA REBRANDS, DEBUTS ON NASDAQ - bernama
Cybin (CYBN) Transitions to Helus Pharma and Moves to Nasdaq - GuruFocus
Cybin to Begin Nasdaq Trading Under New Ticker, Plans to Change Name to Helus Pharma - marketscreener.com
Helus Pharma Rebrands, Moves to Nasdaq as It Advances Late-Stage Mental Health Drugs - TipRanks
Cybin launches $100 million at-the-market equity program By Investing.com - Investing.com Australia
The New Psychedelics: One Dose, Eight Hours, a Therapist on Standby - Bloomberg.com
Cybin (CYBN) Receives a Buy from H.C. Wainwright - The Globe and Mail
Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq in Early January - TipRanks
Cybin to rebrand as Helus Pharma and shift US listing to Nasdaq - MSN
Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq - TipRanks
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq - Business Wire
Cybin to transfer listing from NYSE American to Nasdaq, rebrand - Investing.com
Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - Business Wire
Cybin to Participate in the Jefferies Global Healthcare Conference in London - Business Wire
Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025 - Business Wire
Cybin to Participate at the 2025 Milken Institute Future of Health Summit - Business Wire
Finance Watch: MapLight Brings US Biopharma IPO Tally To 11 In 2025 - Citeline News & Insights
Cybin announces $175 million registered direct offering - marketscreener.com
Cybin Announces $175 Million Registered Direct Offering - Business Wire
Cybin Stock: Optimism Quickly Fades (NYSE:CYBN) - Seeking Alpha
Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones - Business Wire
Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder - Business Wire
Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Business Wire
Helus Pharma Inc (HELP) 재무 분석
Helus Pharma Inc (HELP)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.64%
0.44%
자본화:
|
볼륨(24시간):